FIELD: biotechnology.
SUBSTANCE: disclosed is an antisense oligonucleotide for inhibiting expression of PAPD5 and PAPD7. Also disclosed is a conjugated compound containing said antisense oligonucleotide with a conjugate group attached thereto, and pharmaceutically acceptable salts of an antisense oligonucleotide or a conjugated compound. Invention also relates to a pharmaceutical composition having inhibitory activity on PAPD5 and PAPD7, to use of antisense oligonucleotide and compounds containing it in treatment and/or prevention of HBV infection, in particular chronic HBV infection.
EFFECT: ability to inhibit expression of both PAPD5 and PAPD7 by one molecule of antisense oligonucleotide provides advantages in terms of production, ease of delivery to target cells, simplicity of pharmacokinetics/pharmacodynamics (PK/PD) and required concentration to achieve therapeutic benefit.
27 cl, 18 dwg, 43 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEIC ACID MOLECULES FOR REDUCING THE LEVEL OF PAPD5 OR PAPD7 MRNA FOR TREATING INFECTIOUS HEPATITIS B | 2017 |
|
RU2768699C2 |
| OLIGONUCLEOTIDES FOR REDUCING EXPRESSION OF PD-L1 | 2017 |
|
RU2835926C1 |
| OLIGONUCLEOTIDES FOR LOWERING PD-L1 EXPRESSION | 2017 |
|
RU2747822C2 |
| LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES | 2014 |
|
RU2649367C2 |
| OLIGONUCLEOTIDE CONJUGATES | 2013 |
|
RU2653438C2 |
| MODULATION OF ANDROGEN RECEPTOR EXPRESSION | 2013 |
|
RU2670486C9 |
| COMPOSITIONS AND METHODS FOR MODULATION OF HBV AND TTR EXPRESSION | 2014 |
|
RU2782034C2 |
| COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | 2014 |
|
RU2670614C9 |
| METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS, DIRECTLY ACTING ON CONNECTIVE TISSUE GROWTH FACTOR (CTGF) | 2012 |
|
RU2608655C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2014 |
|
RU2699985C2 |
